Potential US drug tariffs & TrumpRx pricing margin risk [developing]
Key Questions
What is TrumpRx?
TrumpRx is a White House discount drug platform offering popular commercial medications at steep discounts to uninsured patients. It is expanding with participation from companies like AbbVie and Roche/Genentech.
How much is Humira priced on TrumpRx?
Humira is offered on TrumpRx at $950 per month, an 86% discount from its $6,900 list price. This rollout begins this week alongside cheaper biosimilars.
Which AbbVie drugs are being added to TrumpRx?
AbbVie is adding Humira, Synthroid for hypothyroidism, and eye drops including Combigan and Alphagan to the TrumpRx platform.
Is Roche/Genentech participating in TrumpRx?
Yes, Roche's Genentech is joining AbbVie to sell popular commercial drugs on TrumpRx. This expands the platform's offerings.
What potential US drug tariffs are discussed?
Potential tariffs on drugs range from 0-20%, with exemptions for biosimilars. Broader threats include up to 100% levies with loopholes, posing margin risks for companies like AbbVie.
How has AbbVie's stock (ABBV) reacted recently?
AbbVie (ABBV) saw a -3% sell-off amid year-to-date underperformance, closing at $206.69 with a -1.03% drop despite market gains. This follows tariff threats and TrumpRx news.
What risks does AbbVie face from these developments?
AbbVie faces pricing margin risks from TrumpRx discounts and tariffs, layering on pressures from IRA, MFN, 340B, and PBM dynamics. Humira maintains a 72% US market share in 2025.
What should investors watch regarding this highlight?
Investors should monitor policy developments, AbbVie's Q1 earnings call, TrumpRx uptake, and sales volumes. RBC remains positive on Humira, Skyrizi, and Rinvoq.
White House announces 100% tariffs on imported brand drugs without MFN/US mfg commitments; TrumpRx rollout accelerating: AbbVie/Genentech/Roche adding Humira $950 (86% off), Synthroid/Combigan/Alphagan/eye drops, Xofluza starting this week for uninsured alongside biosims; aligns w/ Jan deal/MFN. Prior 0-20% w/ exemptions/biosim free, RBC positive for Humira/Skyrizi-Rinvoq. ABBV -3% sell-off risks amid YTD underperformance/tariff hits layering IRA/MFN/340B/PBM (Humira 72% US share '25). Watches: policy/Q1 call/uptake/volumes.